| 两种新辅助化疗方案治疗进展期胃癌的成本-效果评价 |
| |
| 引用本文： | 陈建时,卢明东,余小挺,郑志强.两种新辅助化疗方案治疗进展期胃癌的成本-效果评价[J].中国综合临床,2010,26(4). |
| |
| 作者姓名： | 陈建时 卢明东 余小挺 郑志强 |
| |
| 作者单位： | 1. 温州医学院附属第二医院普外科胃肠外科,325027
2. 温州医学院附属第一医院妇科 |
| |
| 摘 要： | 目的 评价两种新辅助化疗方案治疗进展期胃癌所产生的经济学效果.方法 2006年1月至2009年3月我院收治的53例进展期胃癌患者分别接受氟尿嘧啶+多西他赛+奥沙利铂(A方案组)和FOLFOX4(B方案组)新辅助化疗,观察其疗效及不良反应,并运用药物经济学的成本-效果分析法对两种方案进行分析评价.结果 两种化疗方案的平均总成本分别为21 320.01元和17 158.50元;化疗有效率为57.14%(16/28)和52.00%(13/25)(P>0.05);相应成本-效果比为373.12和329.97;总不良反应发生率为82.14%(23/28)和76.00%(19/25)(P>0.05).以B方案为基准,增量成本-效果为809.63.结论 B方案是进展期胃癌新辅助化疗的较佳用药方案.
|
| 关 键 词： | 胃肿瘤 新辅助化疗 药物经济学 成本-效果评价 |
A cost-effectiveness analysis of two neoadjuvant chemotherapy schemes for advanced gastric cancer |
| |
| Abstract: | Objective To explore the cost-effectiveness of two neoadjuvant chemotherapy schemes for the treatment of advanced gastric cancer.Methods Fifty-three patients from Jan.2006 to Mar.2009 of advanced gastric cancer underwent the neoadjuvant chemotherapy of Docetaxel+Oxaliplatin+Fluorouracil(scheme A)and FOLFOX4 (scheme B),repectively.Therapeutic efficacy and adverse drug responses (ADRs) were observed.The pharmacoeconomics of cost- effectiveness analysis was performed on two schemes as well.Results The costs were RMB 21 320.01 yuan for scheme A and RMB 17 158.50 yuan for scheme B.The effective rates were 57.14%(16/28) in scheme A and 52.00%(13/25) in scheme B (P>0.05),and the cost-effectiveness ratio were 373.12 and 329.97 per effective rate respectively.The ADRs rates were 82.14%(23/28) and 76.00%(19/25) (P>0.05).The incremental cost- effectiveness ratio was 809.63 of scheme A as against scheme B.Conclusions The scheme B is a better neoadjuvant chemotherapy for advanced gastric cancer. |
| |
| Keywords: | Gastric cancer Neoadjuvant chemotherapy Pharmacoeconomics Cost- effectiveness analysis |
| 本文献已被 万方数据 等数据库收录！ |
|
